PMID- 29331556
OWN - NLM
STAT- MEDLINE
DCOM- 20190816
LR  - 20220331
IS  - 1549-4713 (Electronic)
IS  - 0161-6420 (Linking)
VI  - 125
IP  - 5
DP  - 2018 May
TI  - Polypoidal Choroidal Vasculopathy: Definition, Pathogenesis, Diagnosis, and 
      Management.
PG  - 708-724
LID - S0161-6420(17)32863-4 [pii]
LID - 10.1016/j.ophtha.2017.11.019 [doi]
AB  - Polypoidal choroidal vasculopathy (PCV) is an age-related macular degeneration 
      (AMD) subtype and is seen particularly in Asians. Previous studies have suggested 
      disparity in response to intravitreal injections of anti-vascular endothelial 
      growth factor (VEGF) agents between PCV and typical AMD, and thus, the preferred 
      treatment for PCV has remained unclear. Recent research has provided novel 
      insights into the pathogenesis of PCV, and imaging studies based on OCT suggest 
      that PCV belongs to a spectrum of conditions characterized by pachychoroid, in 
      which disturbance in the choroidal circulation seems to be central to its 
      pathogenesis. Advances in imaging, including enhanced depth imaging, swept-source 
      OCT, en face OCT, and OCT angiography, have facilitated the diagnosis of PCV. 
      Importantly, 2 large, multicenter randomized clinical trials evaluating the 
      safety and efficacy of anti-VEGF monotherapy and combination with photodynamic 
      therapy (PDT) recently reported initial first-year outcomes, providing level I 
      evidence to guide clinicians in choosing the most appropriate therapy for PCV. In 
      this review, we summarize the latest updates in the epidemiologic features, 
      pathogenesis, and advances in imaging and treatment trials, with a focus on the 
      most recent key clinical trials. Finally, we propose current management 
      guidelines and recommendations to help clinicians manage patients with PCV. 
      Remaining gaps in current understanding of PCV, such as significance of polyp 
      closure, high recurrence rate, and heterogeneity within PCV, are highlighted 
      where further research is needed.
CI  - Copyright (c) 2018 American Academy of Ophthalmology. Published by Elsevier Inc. 
      All rights reserved.
FAU - Cheung, Chui Ming Gemmy
AU  - Cheung CMG
AD  - Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, 
      Republic of Singapore; Duke-NUS Medical School, National University of Singapore, 
      Singapore, Republic of Singapore. Electronic address: 
      gemmy.cheung.c.m@singhealth.com.sg.
FAU - Lai, Timothy Y Y
AU  - Lai TYY
AD  - Department of Ophthalmology and Visual Sciences, The Chinese University of Hong 
      Kong, Hong Kong Eye Hospital, Hong Kong, China.
FAU - Ruamviboonsuk, Paisan
AU  - Ruamviboonsuk P
AD  - Department of Ophthalmology, Rajavithi Hospital, Bangkok, Thailand.
FAU - Chen, Shih-Jen
AU  - Chen SJ
AD  - Department of Ophthalmology, Taipei Veterans General Hospital, and School of 
      Medicine, National Yang-Ming University, Taipei, Taiwan.
FAU - Chen, Youxin
AU  - Chen Y
AD  - Department of Ophthalmology, Peking Union Medical College Hospital, Peking Union 
      Medical College and Chinese Academy of Medical Sciences, Beijing, China.
FAU - Freund, K Bailey
AU  - Freund KB
AD  - Vitreous Retina Macula Consultants of New York, and The LuEsther T. Mertz Retinal 
      Research Center, New York, New York; Department of Ophthalmology, New York 
      University School of Medicine, New York, New York.
FAU - Gomi, Fomi
AU  - Gomi F
AD  - Department of Ophthalmology, Hyogo College of Medicine, Hyogo, Japan.
FAU - Koh, Adrian H
AU  - Koh AH
AD  - Eye & Retina Surgeons, Camden Medical Centre, Singapore, Republic of Singapore.
FAU - Lee, Won-Ki
AU  - Lee WK
AD  - Department of Ophthalmology, Seoul St. Mary's Hospital, College of Medicine, The 
      Catholic University of Korea, Seoul, South Korea.
FAU - Wong, Tien Yin
AU  - Wong TY
AD  - Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, 
      Republic of Singapore; Duke-NUS Medical School, National University of Singapore, 
      Singapore, Republic of Singapore.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20180110
PL  - United States
TA  - Ophthalmology
JT  - Ophthalmology
JID - 7802443
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Coloring Agents)
RN  - IX6J1063HV (Indocyanine Green)
MH  - Angiogenesis Inhibitors/therapeutic use
MH  - Choroid/*blood supply
MH  - *Choroidal Neovascularization/diagnosis/etiology/therapy
MH  - Coloring Agents/administration & dosage
MH  - Fluorescein Angiography
MH  - Humans
MH  - Indocyanine Green/administration & dosage
MH  - Macular Degeneration/diagnosis/etiology/therapy
MH  - Photochemotherapy
MH  - *Polyps/diagnosis/etiology/therapy
MH  - Tomography, Optical Coherence
EDAT- 2018/01/15 06:00
MHDA- 2019/08/17 06:00
CRDT- 2018/01/15 06:00
PHST- 2017/09/19 00:00 [received]
PHST- 2017/11/09 00:00 [revised]
PHST- 2017/11/09 00:00 [accepted]
PHST- 2018/01/15 06:00 [pubmed]
PHST- 2019/08/17 06:00 [medline]
PHST- 2018/01/15 06:00 [entrez]
AID - S0161-6420(17)32863-4 [pii]
AID - 10.1016/j.ophtha.2017.11.019 [doi]
PST - ppublish
SO  - Ophthalmology. 2018 May;125(5):708-724. doi: 10.1016/j.ophtha.2017.11.019. Epub 
      2018 Jan 10.